217 related articles for article (PubMed ID: 28042650)
1. Patient satisfaction and preferences of lanreotide Autogel treatment in acromegaly.
Witek P; Mucha S; Ruchała M
Endokrynol Pol; 2016; 67(6):572-579. PubMed ID: 28042650
[TBL] [Abstract][Full Text] [Related]
2. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
Caron P; Bex M; Cullen DR; Feldt-Rasmussen U; Pico Alfonso AM; Pynka S; Racz K; Schopohl J; Tabarin A; Valimaki MJ;
Clin Endocrinol (Oxf); 2004 Jun; 60(6):734-40. PubMed ID: 15163338
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.
Lucas T; Astorga R;
Clin Endocrinol (Oxf); 2006 Sep; 65(3):320-6. PubMed ID: 16918950
[TBL] [Abstract][Full Text] [Related]
4. An international simulated-use study to assess nurses' preferences between two lanreotide syringes for patients with neuroendocrine tumours or acromegaly (PRESTO 3).
Ferone D; Martin W; Williams J; Houchard A; Pommie C; Ribeiro-Oliveira A; Grossman AB
J Endocrinol Invest; 2024 Feb; 47(2):421-432. PubMed ID: 37550552
[TBL] [Abstract][Full Text] [Related]
5. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review.
Mazziotti G; Giustina A
Pituitary; 2010; 13(1):60-7. PubMed ID: 19189218
[TBL] [Abstract][Full Text] [Related]
6. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.
Caron P; Beckers A; Cullen DR; Goth MI; Gutt B; Laurberg P; Pico AM; Valimaki M; Zgliczynski W
J Clin Endocrinol Metab; 2002 Jan; 87(1):99-104. PubMed ID: 11788630
[TBL] [Abstract][Full Text] [Related]
8. Quality of life in patients with acromegaly receiving lanreotide autogel: a real-world observational study.
Bolanowski M; Hubalewska-Dydejczyk A; Kos-Kudła B; Ruchała M; Witek P; Zgliczyński W; Houchard A; Bartmańska M
Endokrynol Pol; 2021; 72(5):512-519. PubMed ID: 34647602
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN).
An Z; Lei T; Duan L; Hu P; Gou Z; Zhang L; Durand-Gasselin L; Wang N; Wang Y; Gu F;
BMC Endocr Disord; 2020 May; 20(1):57. PubMed ID: 32366244
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly.
Bernabéu I; Fajardo C; Marazuela M; Cordido F; Venegas EM; de Pablos-Velasco P; Maroto GP; Olvera MP; de Paz IP; Carvalho D; Romero C; De la Cruz G; Escolá CÁ
Endocrine; 2020 Dec; 70(3):575-583. PubMed ID: 32725444
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly.
Caron P; Cogne M; Raingeard I; Bex-Bachellerie V; Kuhn JM
Clin Endocrinol (Oxf); 2006 Feb; 64(2):209-14. PubMed ID: 16430722
[TBL] [Abstract][Full Text] [Related]
12. A single-center open-label study to investigate the efficacy and safety of repeated subcutaneous injections of lanreotide Autogel in patients with acromegaly previously treated with octreotide.
Kelly P; Maher KT; Chew SL; Monson JP; Grossman AB; Jenkins PJ
Endocr Pract; 2010; 16(2):191-7. PubMed ID: 19833584
[TBL] [Abstract][Full Text] [Related]
13. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel).
Gutt B; Bidlingmaier M; Kretschmar K; Dieterle C; Steffin B; Schopohl J
Exp Clin Endocrinol Diabetes; 2005 Mar; 113(3):139-44. PubMed ID: 15789272
[TBL] [Abstract][Full Text] [Related]
14. Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective.
Bevan JS; Newell-Price J; Wass JA; Atkin SL; Bouloux PM; Chapman J; Davis JR; Howlett TA; Randeva HS; Stewart PM; Viswanath A
Clin Endocrinol (Oxf); 2008 Mar; 68(3):343-9. PubMed ID: 17892497
[TBL] [Abstract][Full Text] [Related]
15. Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study.
Attanasio R; Lanzi R; Losa M; Valentini F; Grimaldi F; De Menis E; Davì MV; Battista C; Castello R; Cremonini N; Razzore P; Rosato F; Montini M; Cozzi R
Endocr Pract; 2008 Oct; 14(7):846-55. PubMed ID: 18996812
[TBL] [Abstract][Full Text] [Related]
16. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly.
Chanson P; Borson-Chazot F; Kuhn JM; Blumberg J; Maisonobe P; Delemer B;
Clin Endocrinol (Oxf); 2008 Aug; 69(2):299-305. PubMed ID: 18248639
[TBL] [Abstract][Full Text] [Related]
17. ACROSTART: A retrospective study of the time to achieve hormonal control with lanreotide Autogel treatment in Spanish patients with acromegaly.
Álvarez-Escolá C; Venegas-Moreno EM; García-Arnés JA; Blanco-Carrera C; Marazuela-Azpiroz M; Gálvez-Moreno MÁ; Menéndez-Torre E; Aller-Pardo J; Salinas-Vert I; Resmini E; Torres-Vela EM; Gonzalo-Redondo MÁ; Vílchez-Joya R; de Miguel-Novoa MP; Halperín-Rabinovich I; Páramo-Fernández C; de la Cruz-Sugranyes G; Houchard A; Picó-Alfonso AM;
Endocrinol Diabetes Nutr (Engl Ed); 2019 May; 66(5):320-329. PubMed ID: 30773338
[TBL] [Abstract][Full Text] [Related]
18. [Somatuline(R) Autogel(R), a new formulation of lanreotide for the treatment of acromegalic patients].
Caron P
Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 3):2S19-24. PubMed ID: 12037499
[TBL] [Abstract][Full Text] [Related]
19. Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies.
Adelman DT; Van Genechten D; Megret CM; Truong Thanh XT; Hand P; Martin WA
Adv Ther; 2019 Dec; 36(12):3409-3423. PubMed ID: 31612358
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR.
Ashwell SG; Bevan JS; Edwards OM; Harris MM; Holmes C; Middleton MA; James RA
Eur J Endocrinol; 2004 Apr; 150(4):473-80. PubMed ID: 15080776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]